The Journal of Thoracic and Cardiovascular Surgery
Volume 133, Issue 2 , Pages 303-308 , February 2007

Data acquisition for the histoculture drug response assay in lung cancer

  • Tatsuya Yoshimasu, MD, PhD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan
    • Corresponding Author InformationAddress for reprints: Tatsuya Yoshimasu, MD, PhD, Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8509, Japan.
    • ,
  • Shoji Oura, MD, PhD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan
    • ,
  • Issei Hirai, MD, PhD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan
    • ,
  • Takeshi Tamaki, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan
    • ,
  • Yozo Kokawa, MD, PhD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan
    • ,
  • Kazuhito Hata, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan
    • ,
  • Fuminori Ohta, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan
    • ,
  • Rie Nakamura, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan
    • ,
  • Mitsumasa Kawago, MD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan
    • ,
  • Hirokazu Tanino, MD, PhD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan
    • ,
  • Yoshitaka Okamura, MD, PhD

      Affiliations

    • Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan
    • ,
  • Tomoko Furukawa, MD, PhD

      Affiliations

    • Analytical Center for Medical Science, SRL, Inc, Tokyo, Japan.

Received 18 December 2005 ,Revised 17 May 2006 ,Accepted 15 June 2006.

References 

  1. Park JG, Kramer BS, Steinberg SM, Carmichael J, Collins JM, Minna JD, et al. Chemosensitivity testing of human colorectal carcinoma cell lines using tetrazolium-based colorimetric assay. Cancer Res. 1987;47:5875–5879
  2. Kobayashi H. Collagen gel droplet culture method to examine in vitro chemosensitivity. Methods Mol Med. 2005;110:59–67
  3. Kobayashi H. Development of a new in vitro chemosensitivity test using collagen gel droplet embedded culture and image analysis for clinical usefulness. Recent Results Cancer Res. 2003;161:48–61
  4. Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, et al. The potential of the histoculture drug response assay to contribute to cancer patient survival. Clin Cancer Res. 1995;1:1537–1543
  5. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res. 1995;1:305–311
  6. Ohie S, Udagawa Y, Aoki D, Nozawa S. Histoculture drug response assay to monitor chemoresponse. Methods Mol Med. 2005;110:79–86
  7. Yoshimasu T, Oura S, Maebeya S, Tanino H, Bessho T, Arimoto J, et al. Histoculture drug response assay on non-small cell lung cancer [in Japanese]. Gan To Kagaku Ryoho. 2000;27:717–722
  8. Yoshimasu T, Oura S, Hirai I, Kokawa Y, Okamura Y, Furukawa T. Dose response curve of paclitaxel measured by histoculture drug response assay [in Japanese]. Gan To Kagaku Ryoho. 2005;32:497–500
  9. Yoshimasu T, Oura S, Hirai I, Kokawa Y, Sasaki R, Honda K, et al. Histoculture drug response assay (HDRA) guided induction concurrent chemoradiotherapy for mediastinal node-positive non-small cell lung cancer [in Japanese]. Gan To Kagaku Ryoho. 2003;30:231–235
  10. Yoshimasu T, Oura S, Hirai I, Kokawa Y, Tanino H, Okamura Y. Chemosensitivity test for lung cancer using biopsy specimens obtained by endoscopic surgery [in Japanese]. Jpn J Chest Surg. 2005;19:82–86
  11. Yoshimasu T, Oura S, Hirai I, Kokawa Y, Hata K, Kawago M, et al. Cutoff level of docetaxel, paclitaxel and gemcitabine in histoculture drug response assay for non-small cell lung cancer [in Japanese]. Gan To Kagaku Ryoho. 2005;32:1013–1016
  12. Gazdar AF, Steinberg SM, Russell EK, Linnoila RI, Oie HK, Ghosh BC, et al. Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J Natl Cancer Inst. 1990;82:117–124
  13. Shaw GL, Gazdar AF, Phelps R, Steinberg SM, Linnoila RI, Johnson BE, et al. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl. 1996;24:173–185
  14. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, et al. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol. 1994;12:1232–1237
  15. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, et al. Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol. 1994;12:1238–1244
  16. Yasuda K, Igishi T, Kawasaki Y, Yamamoto M, Kato K, Matsumoto S, et al. Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Oncology. 2003;65:224–228
  17. Feliu J, Martin G, Lizon J, Chacon JI, Dorta J, de Castro J, et al. Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine (A phase II study). Ann Oncol. 2001;12:1369–1374
  18. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA, et al. Efficacy and safety profile of gemcitabine in non-small cell lung cancer; a phase II study. J Clin Oncol. 1994;12:1535–1540
  19. LeChevalier T, Gottfried M, Gatzemier U, Shepherd FA, Weynants P, Cottier B, et al. Confirmatory activity of gemcitabine in non-small cell lung cancer. Eur J Cancer. 1993;29a(suppl 6):160
  20. Negoro S, Fukuoka M, Kurita Y, Niitani H. Results of phase II studies of gemcitabine in non-small cell lung cancer. Proc Am Soc Clin Oncol. 1994;13:367
  21. Crino L, Mosconi AM, Scagliotti G, De Marinis F, Darwish S, Calandri C, et al. Salvage therapy worth gemcitabine in pretreated advanced non-small cell lung cancer. Proc Am Soc Clin Oncol. 1997;16:446
  22. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 1992;10:16–20
  23. Oshita F, Ikehara M, Sekiyama A, Hamanaka N, Saito H, Yamada K, et al. Genomic-wide cDNA microarray screening to correlate gene expression profile with chemoresistance in patients with advanced lung cancer. J Exp Ther Oncol. 2004;4:155–160
  24. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene. 2003;10:2192–2205

PII: S0022-5223(06)01279-7

doi: 10.1016/j.jtcvs.2006.06.030

The Journal of Thoracic and Cardiovascular Surgery
Volume 133, Issue 2 , Pages 303-308 , February 2007

Article Tools

* Image Usage & Resolution